Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | XBP1 | P17861 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25101398 | 0.91 | ESR1 (0.48) | ESR1ESR2RIPK1CYP17A1ALDH1A1 | |
| SCHEMBL24305005 | 0.88 | ESR1 (0.40) | ESR1ESR2KDM4ECYP17A1HTR7 | |
| SCHEMBL14625003 | 0.87 | ESR1 (0.45) | ESR1ESR2RIPK1KDM4ECYP17A1 | |
| SCHEMBL21791809 | 0.84 | ESR1 (0.43) | ESR1ESR2RIPK1HTR7HPGD | |
| SCHEMBL22955761 | 0.83 | ESR1 (0.46) | ESR1ESR2ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL10178596 | 0.81 | ESR1 (0.36) | ESR1ESR2RIPK1KDM4ECYP17A1 | |
| SCHEMBL24685643 | 0.81 | ESR1 (0.41) | ESR1ESR2RIPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24962192 | 0.79 | ESR1 (0.46) | ESR1ESR2ALDH1A1MEN1KMT2A | |
| SCHEMBL24004027 | 0.79 | ESR1 (0.50) | ESR1ESR2ALDH1A1MEN1NPC1 | |
| SCHEMBL10835512 | 0.79 | ESR1 (0.44) | ESR1ESR2RIPK1KDM4ECYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225620-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, IL2, IFNAR1 | ESR1 4755/4885ESR2 1856/4885RIPK1 126/4885 |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | ESR1 4768/4885ESR2 4317/4885RIPK1 3217/4885 |
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | ESR1 1884/4885ESR2 2708/4885RIPK1 886/4885 |
| US-10836770-B2 | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses | TYK2, IL2, IFNAR1 | ESR1 4358/4885ESR2 1682/4885RIPK1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.